Selonsertib in Adults With Pulmonary Arterial Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.

Also called NCT02234141

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 151 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02234141
  • EudraCT 2014-002131-34
Other papers using this trial's data
  • Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial The Lancet. Respiratory medicine, 2022-01 DOI, PubMed 34425071

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02234141. Randomized; double masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2016-04 (actual). Results posted on 2019-04-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Selonsertib in Adults With Pulmonary Arterial Hypertension
Acronym
ARROW
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Placebo
Intervention (Drug)
Selonsertib
Lead sponsor
Gilead Sciences (class: industry)

Record details

Record id
cardio:ct-nct02234141
Content hash
b018ed40e66612b22484d99c98480121859d1b51122e5c425a1d604827d01185